Clinical Study

Study Designed To Evaluate The Long-Term Safety And Efficacy Of Study Drug (Spd503) In Kids With Attention-Deficit/Hyperactivity Disorder

Posted Date: Jan 14, 2020

  • Investigator: Melissa Delbello
  • Specialties: ADD/ADHD, Psychiatry/Psychology
  • Type of Study: Drug

A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator,Dose-optimization Evaluation followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder


Kids Aged 6 To 17 Years Diagnosed With Adhd With Prior Stimulant Therapy Is Not Suitable, Not Tolerated


Add, Adhd, Children And Adolescents

For More Information:

Veronica Aghera
(513) 558-3314

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.